259 related articles for article (PubMed ID: 35248370)
1. Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma.
Colebatch AJ; Paver EC; Vergara IA; Thompson JF; Long GV; Wilmott JS; Scolyer RA
Pathology; 2022 Aug; 54(5):533-540. PubMed ID: 35248370
[TBL] [Abstract][Full Text] [Related]
2. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.
Wiesner T; Kutzner H; Cerroni L; Mihm MC; Busam KJ; Murali R
Pathology; 2016 Feb; 48(2):113-31. PubMed ID: 27020384
[TBL] [Abstract][Full Text] [Related]
3. Massively parallel sequencing analysis of benign melanocytic naevi.
Lozada JR; Geyer FC; Selenica P; Brown D; Alemar B; Merghoub T; Berger MF; Busam KJ; Halpern AC; Weigelt B; Reis-Filho JS; Hollmann TJ
Histopathology; 2019 Jul; 75(1):29-38. PubMed ID: 30791119
[TBL] [Abstract][Full Text] [Related]
4. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.
Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G
Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459
[TBL] [Abstract][Full Text] [Related]
5. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
6. Mutational status of naevus-associated melanomas.
Shitara D; Tell-Martí G; Badenas C; Enokihara MM; Alós L; Larque AB; Michalany N; Puig-Butille JA; Carrera C; Malvehy J; Puig S; Bagatin E
Br J Dermatol; 2015 Sep; 173(3):671-80. PubMed ID: 25857817
[TBL] [Abstract][Full Text] [Related]
7. Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo.
Tschandl P; Berghoff AS; Preusser M; Pammer J; Pehamberger H; Kittler H
Br J Dermatol; 2016 Feb; 174(2):364-70. PubMed ID: 26613644
[TBL] [Abstract][Full Text] [Related]
8. Defining the Molecular Genetics of Dermoscopic Naevus Patterns.
Tan JM; Tom LN; Soyer HP; Stark MS
Dermatology; 2019; 235(1):19-34. PubMed ID: 30332666
[TBL] [Abstract][Full Text] [Related]
9. The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive mitogen-activated protein kinase pathway activation.
Tan JM; Tom LN; Jagirdar K; Lambie D; Schaider H; Sturm RA; Soyer HP; Stark MS
Br J Dermatol; 2018 Jan; 178(1):191-197. PubMed ID: 28714107
[TBL] [Abstract][Full Text] [Related]
10. Restrospective reappraisal of the prognostic classification of spitzoid melanocytic neoplasms after BRAF and NRAS mutation characterisation: a single institution experience.
Moysset I; Castrejon N; Garcia-Herrera A; Castillo P; Marginet M; Teixido C; Podlipnik S; Albero-Gonzalez R; Montironi C; Navarro J; Rovira C; Puig S; Carrera C; Alos L
Histopathology; 2024 Jun; 84(7):1154-1166. PubMed ID: 38409889
[TBL] [Abstract][Full Text] [Related]
11. Biology and genetics of acquired and congenital melanocytic naevi.
Maher NG; Scolyer RA; Colebatch AJ
Pathology; 2023 Mar; 55(2):169-177. PubMed ID: 36635156
[TBL] [Abstract][Full Text] [Related]
12. The Genetic Evolution of Melanoma from Precursor Lesions.
Shain AH; Yeh I; Kovalyshyn I; Sriharan A; Talevich E; Gagnon A; Dummer R; North J; Pincus L; Ruben B; Rickaby W; D'Arrigo C; Robson A; Bastian BC
N Engl J Med; 2015 Nov; 373(20):1926-36. PubMed ID: 26559571
[TBL] [Abstract][Full Text] [Related]
13. Melanocytic naevi, melanocytomas and emerging concepts.
Yeh I
Pathology; 2023 Mar; 55(2):178-186. PubMed ID: 36642570
[TBL] [Abstract][Full Text] [Related]
14. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.
Akslen LA; Puntervoll H; Bachmann IM; Straume O; Vuhahula E; Kumar R; Molven A
Melanoma Res; 2008 Feb; 18(1):29-35. PubMed ID: 18227705
[TBL] [Abstract][Full Text] [Related]
15. Spitz melanocytic tumours - a review.
Yeh I; Busam KJ
Histopathology; 2022 Jan; 80(1):122-134. PubMed ID: 34958498
[TBL] [Abstract][Full Text] [Related]
16. Melanocytic lesions, Spitz tumors, and Don Ferrante's logic.
Urso C
Am J Dermatopathol; 2007 Oct; 29(5):491-4. PubMed ID: 17890925
[No Abstract] [Full Text] [Related]
17. High BRAF mutation frequency does not characterize all melanocytic tumor types.
Saldanha G; Purnell D; Fletcher A; Potter L; Gillies A; Pringle JH
Int J Cancer; 2004 Sep; 111(5):705-10. PubMed ID: 15252839
[TBL] [Abstract][Full Text] [Related]
18. Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion.
Takata M; Lin J; Takayanagi S; Suzuki T; Ansai S; Kimura T; Cerroni L; Saida T
Br J Dermatol; 2007 Jun; 156(6):1287-94. PubMed ID: 17535228
[TBL] [Abstract][Full Text] [Related]
19. The genomic landscape of childhood and adolescent melanoma.
Lu C; Zhang J; Nagahawatte P; Easton J; Lee S; Liu Z; Ding L; Wyczalkowski MA; Valentine M; Navid F; Mulder H; Tatevossian RG; Dalton J; Davenport J; Yin Z; Edmonson M; Rusch M; Wu G; Li Y; Parker M; Hedlund E; Shurtleff S; Raimondi S; Bhavin V; Donald Y; Mardis ER; Wilson RK; Evans WE; Ellison DW; Pounds S; Dyer M; Downing JR; Pappo A; Bahrami A
J Invest Dermatol; 2015 Mar; 135(3):816-823. PubMed ID: 25268584
[TBL] [Abstract][Full Text] [Related]
20. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
